Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 9:58 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 9,138 matching trials from the live ClinicalTrials.gov search.
Approved For Marketing No phase listed Expanded access

Axicabtagene Ciloleucel Expanded Access Study

NCT03153462
Conditions
Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma, Relapsed/Refractory Transformed Follicular Lymphoma, Relapsed/Refractory High-Grade B-Cell Lymphoma
Interventions
Axicabtagene Ciloleucel
Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
U.S. locations
15
States / cities
Duarte, California • Stanford, California • Miami, Florida + 12 more
Conditions
Waldenström Macroglobulinemia
Interventions
Daratumumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
Conditions
Lewy Body Disease
Interventions
18F-Flortaucipir
Drug
Lead sponsor
Kejal Kantarci
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Mantle Cell Lymphoma
Interventions
Venetoclax, Bendamustine, Rituximab
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Urbana, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 4 more
Conditions
Glioblastoma, IDH-Wildtype
Interventions
Archive Sample Retrieval, Biospecimen Collection, Chest Radiography, Echocardiography Test, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Temozolomide
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Breast Cancer
Interventions
CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine, incomplete Freund's adjuvant, sargramostim, immunoenzyme technique, immunologic technique
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Glioblastoma (GBM)
Interventions
MT-125
Drug
Lead sponsor
Myosin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Breast Carcinoma, Esophageal Carcinoma, Head and Neck Carcinoma, Lung Carcinoma, Malignant Brain Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Terminated Phase 3 Interventional Results available

Phase 3 Extension Study of Dexpramipexole in ALS

NCT01622088
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Phoenix, Arizona • Fresno, California • Orange, California + 38 more
Completed Not applicable Interventional Results available

Effects of Pneumatic Vitreolysis on Macular Hole

NCT03677869
Conditions
Vitreomacular Traction (VMT), Full-thickness Macular Holes (MH)
Interventions
Intraocular gas (C3F8)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
45
States / cities
Campbell, California • Huntington Beach, California • Mountain View, California + 39 more
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography with Contrast, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
CAM2029, Octreotide LAR, Lanreotide ATG
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 12 more
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
antisense oligonucleotide, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
La Jolla, California • Rochester, Minnesota • Nashville, Tennessee
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
triapine, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
PRGN-3006 T Cells
Drug
Lead sponsor
Precigen, Inc
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Tampa, Florida • Rochester, Minnesota
Conditions
Post-Operative Complications in Cardiac Surgery
Interventions
RBT-1, Placebo
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
29
States / cities
Huntsville, Alabama • San Francisco, California • Stanford, California + 25 more
Conditions
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Interventions
Placebo, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
54
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
Conditions
Leukemia
Interventions
temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
14
States / cities
Stanford, California • Indianapolis, Indiana • Minneapolis, Minnesota + 11 more
Conditions
Leukemia
Interventions
mercaptopurine, methotrexate, tretinoin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
210
States / cities
Scottsdale, Arizona • Roseville, California • Sacramento, California + 135 more
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Placebo, Solabegron (GW427353)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Adolescent Idiopathic Scoliosis
Interventions
MID-C System
Device
Lead sponsor
Apifix
Industry
Eligibility
10 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
14
States / cities
San Diego, California • Jacksonville, Florida • Atlanta, Georgia + 11 more
Conditions
Prostate Cancer
Interventions
Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
6
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • New York, New York + 2 more
Completed Not applicable Interventional Results available

Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology

NCT01359046
Conditions
Infection Associated With Catheter, Urinary Tract Infection
Interventions
silver SPC, standard SPC
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Interventions
Dacogen
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota